Beam Therapeutics Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Beam Therapeutics Inc. (BEAM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-24
- Beam Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -1.60%.
- Beam Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -2.50%.
- Beam Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -1.80%.
- Beam Therapeutics Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -1.60% 10-K · filed 2026-02-24 | |
| 2023-12-31 | -2.50% 10-K · filed 2026-02-24 | 2.50% 10-K · filed 2024-02-27 |
| 2022-12-31 | -1.80% 10-K · filed 2025-02-25 | 1.80% 10-K · filed 2023-02-28 |
| 2021-12-31 | -0.70% 10-K · filed 2024-02-27 | |
| 2020-12-31 | -0.80% 10-K · filed 2023-02-28 | |
| 2019-12-31 | 1.80% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |